MoonLake Immunotherapeutics (MLTX)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 2 (below the required floor of 3) — a hard block that suppresses any long entry regardless of chart quality; both a pullback-to-support limit and a breakout stop were reviewed and neither is emitted under the override.
Company overview
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing Sonelokimab, a Nanobody-based treatment for inflammatory diseases. The company is conducting Phase II trials for conditions including hidradenitis suppurativa and psoriatic arthritis.
Fundamental
weakMoonLake's fundamentals are speculative, driven by a single asset and cash burn, but supported by strong liquidity and a pending FDA decision.
Pre-revenue, single-asset immunology company with no earnings history and widening cash burn, offset by a genuinely strong $498.5 million liquidity cushion, a covenant-compliant secured facility with no amortisation before 2030 and a BLA for sonelokimab in hidradenitis suppurativa now filed with the FDA. Binary regulatory risk, persistent dilution, insider selling and a pending securities class action outweigh the balance-sheet strength, leaving a speculative, catalyst-driven profile rather than an investment-grade fundamental story.
Sentiment
fairSentiment is mixed, with a pending FDA decision creating a binary catalyst amid insider selling and a recent target cut.
The dominant driver is an unresolved FDA review: MoonLake has filed a BLA for sonelokimab in hidradenitis suppurativa with a filing/acceptance decision expected by end-November 2026 and a priority-review decision expected in mid-December (announced confidence), and in-window coverage of that regulatory progress scored net-positive even as the 2026-11-04 Q3 print drew negative reception for a loss that exceeded estimates and a consensus 12-month target cut to $30. The sentiment delta is flat rather than improving (baseline polarity_score about +0.13 versus scoring about +0.12, both windows measured with n greater than or equal to 3), retail sentiment is indeterminate because Reddit access was blocked, and a moderate red-flag cap applies for conflicting catalyst signals; no severe flag is present.
Technical
fairTechnicals show a short-term uptrend within a broken primary trend, with constructive pullback and adequate liquidity.
Technical score 3: the short-term structure is constructive — price 12.50 sits above the SMA20 (11.82), SMA50 (11.88), EMA9 (12.38) and EMA21 (12.00) stack, MACD is above zero and above its signal with an expanding positive histogram, and the two-session pullback from the 2026-11-11 high 13.90 has come on declining volume. Against that, the primary trend is still broken (price 12.50 versus SMA200 16.26, and below DEMA14 12.61 / TEMA14 12.92), ADX is easing from 34.19 to 26.72, and two consecutive down sessions leave the tape mixed — real but not strong enough to score above 3. The score is preserved (not capped) because no indicator-integrity or stale-feed failure occurred; the trade is nonetheless blocked by the fundamental override.
You’re looking at 2026-11-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

